PharmiWeb.com - Global Pharma News & Resources
01-Feb-2019

Neuraxpharm acquires Farmax to expand its pan-European footprint in Central and Eastern Europe

·                     Neuraxpharm reinforces its European CNS leadership position by entering Czech Republic, Slovakia and Hungary

 

·                     Farmax is a Central and Eastern European CNS specialist pharma carve-out from SVUS Pharma

 

February 1st, 2019. Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of central nervous system disorders (CNS), announces the acquisition of Farmax, a CNS specialty pharmaceutical company, from SVUS Pharma.

 

Farmax, located in Hradec Králové, Czech Republic, was the commercial division of SVUS Pharma, and has a strong distribution presence in the Czech Republic, Slovakia as well as a small presence in Hungary. Farmax is a leader in sales and marketing both branded and non-branded generics pharmaceuticals for CNS disorders such as Zolpinox®. It also commercializes well-known OTC nutraceuticals such as Preventan® and Maxicor®.

Farmax has been renamed Neuraxpharm Bohemia and will commercialize its products under the Neuraxpharm brand. Leveraging its proprietary sales force in the Czech Republic, Slovakia and Hungary, Neuraxpharm Bohemia plans to quickly offer new and differentiated products to local patients and healthcare providers based on the group’s broad CNS portfolio.

Dr. Jörg Thomas Dierks, CEO of Neuraxpharm, commented: “We are pleased to welcome Farmax to the Neuraxpharm family. We truly believe that this acquisition will strengthen our leading position in the European CNS market and provide us direct access to the Central and Eastern European (CEE) markets with our own sales force. Entering the CEE region is one of the pillars of the Neuraxpharm strategy as these markets offer an attractive growth potential.”

Dr. Lukáš Jirka, previously SVUS Pharma General Manager and now General Manager at Neuraxpharm Bohemia, added: “I am delighted to join Neuraxpharm and become part of a leading European CNS franchise. I am very proud of SVUS Pharma’s achievements in the Czech Republic and the whole CEE region. I would like to thank the management and employees of SVUS Pharma for their dedication and commitment. We will certainly contribute with our expertise in the CNS area to make the Neuraxpharm Group an even stronger player in the European CNS market.”

The terms of the transaction were not disclosed.

 

 

About Neuraxpharm

Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of central nervous system disorders (CNS) with a direct presence in Germany, Spain, Italy, France, Poland, Czech Republic, Slovakia and Hungary. Consolidated as a group in 2016 and backed by funds advised by Apax Partners, Neuraxpharm has a unique understanding of the CNS market of over 30 years.

 

Neuraxpharm develops and commercializes in Europe branded and generic CNS pharmaceuticals and nutraceuticals, offering a wide range of effective, differentiated and affordable CNS treatments, aimed at patients as well as health professionals and industry partners.

 

Present in more than 50 countries, Neuraxpharm also manufactures pharmaceutical forms and active pharmaceutical ingredients indicated for the CNS and respiratory areas.

 

www.neuraxpharm.com

 

About SVUS Pharma

SVUS Pharma is a leader in contract pharmaceutical manufacturing in the Czech Market. Founded in 1923 and located in Hradec Králové, the company is a pharmaceutical packaging and labelling specialist, offering proven solutions for primary and secondary packing projects. SVUS Pharma’s combined capabilities enable a robust portfolio of activates for the primary packaging and labelling of soft gel, hard gel capsules, as well as solid and semi solid formulation of OTC, Rx and food supplements.

http://www.svus.cz/

 

 

For more information, contact ATREVIA:

Sergi Muñozsmmolins@atrevia.com  +34 667 631 681

Cristina Massanacmassana@atrevia.com  +34 689 046 835

 

Editor Details

Last Updated: 01-Feb-2019